NIST Center for Neutron Research, National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, United States.
Novavax, Inc., 21 Firstfield Road, Gaithersburg, Maryland 20878, United States.
Mol Pharm. 2021 Jan 4;18(1):359-376. doi: 10.1021/acs.molpharmaceut.0c00986. Epub 2020 Dec 15.
The respiratory syncytial virus (RSV) fusion (F) protein/polysorbate 80 (PS80) nanoparticle vaccine is the most clinically advanced vaccine for maternal immunization and protection of newborns against RSV infection. It is composed of a near-full-length RSV F glycoprotein, with an intact membrane domain, formulated into a stable nanoparticle with PS80 detergent. To understand the structural basis for the efficacy of the vaccine, a comprehensive study of its structure and hydrodynamic properties in solution was performed. Small-angle neutron scattering experiments indicate that the nanoparticle contains an average of 350 PS80 molecules, which form a cylindrical micellar core structure and five RSV F trimers that are arranged around the long axis of the PS80 core. All-atom models of full-length RSV F trimers were built from crystal structures of the soluble ectodomain and arranged around the long axis of the PS80 core, allowing for the generation of an ensemble of conformations that agree with small-angle neutron and X-ray scattering data as well as transmission electron microscopy (TEM) images. Furthermore, the hydrodynamic size of the RSV F nanoparticle was found to be modulated by the molar ratio of PS80 to protein, suggesting a mechanism for nanoparticle assembly involving addition of RSV F trimers to and growth along the long axis of the PS80 core. This study provides structural details of antigen presentation and conformation in the RSV F nanoparticle vaccine, helping to explain the induction of broad immunity and observed clinical efficacy. Small-angle scattering methods provide a general strategy to visualize surface glycoproteins from other pathogens and to structurally characterize nanoparticle vaccines.
呼吸道合胞病毒(RSV)融合(F)蛋白/聚山梨醇酯 80(PS80)纳米颗粒疫苗是用于母体免疫接种和保护新生儿免受 RSV 感染的最具临床进展的疫苗。它由接近全长的 RSV F 糖蛋白组成,具有完整的膜结构域,与 PS80 去污剂配制成稳定的纳米颗粒。为了了解疫苗的功效的结构基础,对其结构和溶液中的流体力学性质进行了全面研究。小角中子散射实验表明,纳米颗粒含有平均 350 个 PS80 分子,形成圆柱形胶束核心结构和 5 个 RSV F 三聚体,它们围绕 PS80 核心的长轴排列。全长 RSV F 三聚体的全原子模型是根据可溶性外域的晶体结构构建的,并围绕 PS80 核心的长轴排列,从而生成与小角中子和 X 射线散射数据以及透射电子显微镜(TEM)图像一致的构象集合。此外,发现 RSV F 纳米颗粒的流体力学尺寸可通过 PS80 与蛋白质的摩尔比来调节,这表明纳米颗粒组装的机制涉及 RSV F 三聚体的添加和沿着 PS80 核心的长轴生长。该研究提供了 RSV F 纳米颗粒疫苗中抗原呈递和构象的结构细节,有助于解释广泛免疫的诱导和观察到的临床疗效。小角度散射方法为可视化其他病原体的表面糖蛋白和结构表征纳米颗粒疫苗提供了一种通用策略。